Who are Maxipime's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ancef In Sodium Chloride 0.9% In Plastic Container, Single Agent IV Antibiotic Therapy - MSSA, Beta-lactam antibiotic, anti-pseudomonal penicillin, Cefepime, Meropenem, or Piperacillin/Tazobactam, azithromycin and cefixime.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefepime-hydrochloride.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Maxipime — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maxipime (Cefepime Hydrochloride) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cephalosporin. Area: Infectious Disease.

marketed Cephalosporin Bacterial cell wall peptidoglycan Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Maxipime (Cefepime Hydrochloride) — Baxter. Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Maxipime TARGET	Cefepime Hydrochloride	Baxter	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Ancef In Sodium Chloride 0.9% In Plastic Container	Cefazolin Sodium	GSK	marketed	Cephalosporin	Bacterial cell wall peptidoglycan	1973-01-01
Single Agent IV Antibiotic Therapy - MSSA	Single Agent IV Antibiotic Therapy - MSSA	West Virginia University	marketed	Beta-lactam antibiotic	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Beta-lactam antibiotic	Beta-lactam antibiotic	University Hospital, Ghent	marketed	Beta-lactam antibiotic	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
anti-pseudomonal penicillin	anti-pseudomonal penicillin	Vanderbilt University Medical Center	marketed	Beta-lactam antibiotic (anti-pseudomonal penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Cefepime, Meropenem, or Piperacillin/Tazobactam	Cefepime, Meropenem, or Piperacillin/Tazobactam	University of Florida	marketed	Beta-lactam antibiotic (cephalosporin, carbapenem, or aminopenicillin with beta-lactamase inhibitor)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
azithromycin and cefixime	azithromycin and cefixime	Sheba Medical Center	marketed	Combination antibiotic (macrolide + third-generation cephalosporin)	Bacterial 50S ribosome (azithromycin); bacterial cell wall peptidoglycan (cefixime)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cephalosporin class)

Baxter · 1 drug in this class
GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Maxipime — Competitive Intelligence Brief. https://druglandscape.com/ci/cefepime-hydrochloride. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing